Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer

BMB Reports

Volumn 47, Issue 1, 2014, Pages 33-38

  Li, Jia ^a   Jiang, Kuo ^b   Qiu, Xiuchun ^b   Li, Meng ^c   Hao, Qiang ^c   Wei, Li ^a   Zhang, Wei ^c   Chen, BiLiang ^a   Xin, Xiaoyan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; CXCR4; Epithelial ovarian cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CXCR4 PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, CXCR4; RNA INTERFERENCE; RNA, SMALL INTERFERING; S PHASE CELL CYCLE CHECKPOINTS; UP-REGULATION;

EID: 84893411363     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.1.069     Document Type: Article

References (21)

1. Siegel, R., Naishadham, D. and Jemal, A. (2012) Cancer statistics, 2012. CA 62, 10-29.
2. Sudo, T. (2012) Molecular-targeted therapies for ovarian cancer: prospects for the future. Int. J. Clin. Oncol. 17, 424-429.
3. Sueblinvong, T., Ghebre, R., Iizuka, Y., Pambuccian, S. E., Isaksson Vogel, R., Skubitz, A. P. and Bazzaro, M. (2012) Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors. PLOS One 7, e50519.
4. Teicher, B. A. and Fricker, S. P. (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 16, 2927-2931.
5. Ying, J., Xu, Q., Zhang, G., Liu, B. and Zhu, L. (2012) The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Med. Oncol. 29, 1716-1722.
6. Yang, S. X., Loo, W. T., Chow, L. W., Yang, X. H., Zhan, Y., Fan, L. J., Zhang, F., Chen, L., Wang, Q. L., Xiao, H. L., Wu, J. L., Bian, X. W. and Jiang, J. (2012) Decreased expression of C-erbB-2 and CXCR4 in breast cancer after primary chemotherapy. J. Transl. Med. 10 (Suppl 1), S3.
7. Murakami, T., Kawada, K., Iwamoto, M., Akagami, M., Hida, K., Nakanishi, Y., Kanda, K., Kawada, M., Seno, H., Taketo, M. M. and Sakai, Y. (2013) The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int. J. Cancer 132, 276-287.
8. Jung, M. J., Rho, J. K., Kim, Y. M., Jung, J. E., Jin, Y. B., Ko, Y. G., Lee, J. S., Lee, S. J., Lee, J. C. and Park, M. J. (2013) Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 32, 209-221.
9. Sekiya, R., Kajiyama, H., Sakai, K., Umezu, T., Mizuno, M., Shibata, K., Yamamoto, E., Fujiwara, S., Nagasaka, T. and Kikkawa, F. (2012) Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary. Hum. Pathol. 43, 904-910.
10. Domanska, U. M., Timmer-Bosscha, H., Nagengast, W. B., Oude Munnink, T. H., Kruizinga, R. C., Ananias, H. J., Kliphuis, N. M., Huls, G., De Vries, E. G., de Jong, I. J. and Walenkamp, A. M. (2012) CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 14, 709-718.
11. Yu, T., Wu, Y., Huang, Y., Yan, C., Liu, Y., Wang, Z., Wang, X., Wen, Y., Wang, C. and Li, L. (2012) RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis. Mol. Ther 20, 398-407.
12. Chen, G., Chen, S. M., Wang, X., Ding, X. F., Ding, J. and Meng, L. H. (2012) Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J. Biol. Chem. 287, 12132-12141.
13. Dubrovska, A., Elliott, J., Salamone, R. J., Telegeev, G. D., Stakhovsky, A. E., Schepotin, I. B., Yan, F., Wang, Y., Bouchez, L. C., Kularatne, S. A., Watson, J., Trussell, C., Reddy, V. A., Cho, C. Y. and Schultz, P. G. (2012) CXCR4 expression in prostate cancer progenitor cells. PLOS One 7, e31226.
14. Dubrovska, A., Hartung, A., Bouchez, L. C., Walker, J. R., Reddy, V. A., Cho, C. Y. and Schultz, P. G. (2012) CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Brit. J. Cancer 107, 43-52.
15. Wang, J., Cai, J., Han, F., Yang, C., Tong, Q., Cao, T., Wu, L. and Wang, Z. (2011) Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway. Int. J. Gynecol. Cancer 21, 981-987.
16. Kim, J., Yip, M. L., Shen, X., Li, H., Hsin, L. Y., Labarge, S., Heinrich, E. L., Lee, W., Lu, J. and Vaidehi, N. (2012) Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. PLOS One 7, e31004.
17. Guo, P., You, J. O., Yang, J., Moses, M. A. and Auguste, D. T. (2012) Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials 33, 8104-8110.
18. Zhou, Z., Chen, Z. W., Yang, X. H., Shen, L., Ai, X. H., Lu, S. and Luo, Q. Q. (2012) Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer. J. Exp. Clin. Canc. Res. 31, 34.
19. Wang, L., Huang, T., Chen, W., Gao, X., Zhou, T., Wu, Z. and Sun, Y. (2012) Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells. Oncol. Rep. 28, 2043-2048.
20. Scala, S., Ottaiano, A., Ascierto, P. A., Cavalli, M., Simeone, E., Giuliano, P., Napolitano, M., Franco, R., Botti, G. and Castello, G. (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin. Cancer Res. 11, 1835-1841.
21. Kim, M., Koh, Y. J., Kim, K. E., Koh, B. I., Nam, D. H., Alitalo, K., Kim, I. and Koh, G. Y. (2010) CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 70, 10411-10421.